Skip to main content
Log in

Anti-diabetic and toxic effects of vanadium compounds

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Compounds of the trace element vanadium have been shown to mimic insulin in in vitro and in vivo systems. These compounds have been found to exert anti-diabetic effects in rodent models of type 1 and type 2 diabetes mellitus as well as in a limited number of studies in human diabetic subjects. Thus, vanadium compounds have emerged as agents for potential use in diabetes therapy. However, treatment of diabetic animals with inorganic vanadium salts has also been associated with some toxic side-effects such as gastrointestinal discomfort and decreased body weight gain. In addition, vanadium salts have been reported to exert toxic effects on the liver and kidney. More recently, it was shown that organic vanadium compounds were much safer than inorganic vanadium salts and did not cause any gastrointestinal discomfort, hepatic or renal toxicity. This review briefly summarizes the anti-diabetic and toxic effects of vanadium compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chasteen ND: The biochemistry of vanadium. In: Structure and Bonding. Springer Verlag, Berlin, Heidelberg, 1983, pp 105-138

    Google Scholar 

  2. Srivastava AK: Potential use of vanadium compounds in the treatment of diabetes mellitus. Exp Opin Invest Drugs 4: 525-536, 1995

    Google Scholar 

  3. Lyonnet B, Martz M, Martin E: L'emploi thérapeutique des dérivés du vanadium. La Presse Médicale 32: 191-192, 1899

    Google Scholar 

  4. Tolman EL, Barris E, Bums M, Pansini A, Partridge R: Effects of vanadium on glucose metabolism in vitro. Life Sci 25: 1159-1164, 1979

    Google Scholar 

  5. Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39: 1-5, 1990

    Google Scholar 

  6. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1477, 1985

    Google Scholar 

  7. Brichard SM, Lederer J, Henquin J-C: The insulin-like properties of vanadium: A curiosity or a perspective for the treatment of diabetes? Diabetes Metab 17: 435-440, 1991

    Google Scholar 

  8. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 188: 73-80, 1998

    Google Scholar 

  9. McNeill JH, Yuen VG, Hoveyda HR, Orvig C: Bis(maltolato)-oxovanadium (IV) is a potent insulin mimic. J Med Chem 35: 1489-1491, 1992

    Google Scholar 

  10. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium compounds: A new class of potent phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994

    Google Scholar 

  11. Shisheva A, Ikonomov O, Shechter Y: The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats. Endocrinology 134: 507-510, 1994

    Google Scholar 

  12. Karasik A, Hattori M: Use of animal models in the study of diabetes. In: C.R. Kahn, G.C. Weir (eds). Jolin's Diabetes Mellitus. Lea and Febiger, Philadelphia, 1994, pp 317-350

    Google Scholar 

  13. Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J Biol Chem 262: 6658-6662, 1987

    Google Scholar 

  14. Gil J, Miralpeix M, Carreras J, Bartrons R: Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats. J Biol Chem 263: 1868-1871, 1988

    Google Scholar 

  15. Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123: 2048-2053, 1988

    Google Scholar 

  16. Blondel O, Bailbe D, Portha B: In vivo insulin resistance in streptozotocindiabetic rats-evidence for reversal following oral vanadate treatment. Diabetologia 32: 185-190, 1989

    Google Scholar 

  17. Bendayan M, Gingras D: Effects of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocindiabetic rats. Diabetologia 32: 561-567, 1989

    Google Scholar 

  18. Ramanadham, S, Mongold J-J, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257: H904-H911, 1989

    Google Scholar 

  19. Bollen M, Miralpeix M, Ventura F, Toth B, Bartrons R, Stalmans W: Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase. Biochem J 267: 269-271, 1990

    Google Scholar 

  20. Strout HV, Vicario PP, Biswas C, Superstein R, Brady EJ, Pilch PF, Berger J: Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin responsive glucose transporter in skeletal muscle. Endocrinology 126: 2728-2732, 1990

    Google Scholar 

  21. Sekar N, Kanthasamy A, William S, Subramanian S, Govindasamy S: Insulin actions of vanadate in diabetic rats. Pharmacol Res 22: 207-217, 1989

    Google Scholar 

  22. Sakurai H, Tsuchiya K, Nukatsuka M, Sofue M, Kawada J: Insulin-like effects of vanadyl ion in streptozotocin-induced diabetic rats. J Endocrinol 126: 451-459, 1990

    Google Scholar 

  23. Pugazhenthi S, Khandelwal RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 39: 821-827, 1990

    Google Scholar 

  24. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899, 1989

    Google Scholar 

  25. Venkatesan N, Avidan A, Davidson MB: Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 40: 492-498, 1991

    Google Scholar 

  26. Saxena AK, Srivastava P, Bacquer NZ: Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and-independent tissues of diabetic rats. Eur J Pharmacol 216: 123-126, 1992

    Google Scholar 

  27. Madsen KL, Porter VM, Fedorak RN: Oral vanadate reduces Na(+)-dependent glucose transport in rat small intestine. Diabetes 42: 1126-1132, 1993

    Google Scholar 

  28. Valera A, Rodriguez-Gil JE, Bosch F: Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. J Clin Invest 92: 4-11, 1993

    Google Scholar 

  29. Malabu. UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43: 9-15, 1994

    Google Scholar 

  30. Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH: Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 38: 1390-1395, 1989

    Google Scholar 

  31. Yuen VG, Orvig G, McNeill JH: Glucose lowering effect of a new organic vanadium complex, bis(maltolato)oxovanadium (IV). Can J Physiol Pharmacol 71: 263-269, 1993

    Google Scholar 

  32. Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium (VI). Can J Physiol Pharmacol 71: 270-276, 1993

    Google Scholar 

  33. Reul BA, Amin SS, Buchet JP, Ongemba L-N, Crans DC, Brichard SM: Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol 126: 4674-4677, 1999

    Google Scholar 

  34. Yale J-F, Lachance D, Bevan AP, Vigeant C, Shaver A, Posner BI: Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats. Diabetes 44: 1274-1279, 1995

    Google Scholar 

  35. Brichard SM, Pottier AM, Henquin JC: Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 125: 2510-2516, 1989

    Google Scholar 

  36. Pugazhenthi S, Angel JF, Khandelwal RL: Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 40: 941-946, 1991

    Google Scholar 

  37. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87: 1286-1294, 1991

    Google Scholar 

  38. Brichard SM, Bailey CJ, Henquin J-C: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326-1332, 1990

    Google Scholar 

  39. Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH: Effects of low and high dose administration of bis(maltolato)oxovanadium (IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 74: 1001-1009, 1996

    Google Scholar 

  40. Goldfine AB, Simonson DC, Folli F, Patti M-E, Kahn CR: In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 153: 217-231, 1995

    Google Scholar 

  41. Cohen N, Halberstam M, Shlimovich P, Chang O, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995

    Google Scholar 

  42. Boden G, Chen X, Ruiz J, van Rossum DV, Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45: 1130-1135, 1996

    Google Scholar 

  43. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45: 659-666, 1996

    Google Scholar 

  44. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL: Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation. Mol Cell Biochem 153: 233-240, 1995

    Google Scholar 

  45. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL: Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 66: 279-287, 1991

    Google Scholar 

  46. Oster MH, Llobet JM, Domingo JL, German JB, Keen CL: Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and prooxidant effects. Toxicology 83: 115-130, 1993

    Google Scholar 

  47. Nechay BR, Nanninga LB, Nechay PSE, Post RL, Grantham JJ, Macara IG, Kubena LF, Phillips TD, Nielsen FH: Role of vanadium in biology. Fed Proc 45: 123-132, 1986

    Google Scholar 

  48. Al-Bayati MA, Giri SN, Raah OG: Time and dose response study of the effects of vanadate in rats: Changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium and inorganic phosphate. J Environ Pathol Toxicol Oncol 10: 206-213, 1990

    Google Scholar 

  49. Bishayee A, Cecchin F: Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol Trace Element Res 48: 275-285, 1995

    Google Scholar 

  50. Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill JH, Serrano JJ: Toxicological aspects of vanadyl sulphate on diabetic rats: Effects on vanadium levels and pancreatic b-cell morphology. Pharmacol Toxicol 67: 192-198, 1990

    Google Scholar 

  51. Sanchez MT, Domingo JL: Effects of vanadium on activity and learning in rats. Physiol Behav 63: 345-350, 1998

    Google Scholar 

  52. Wang H, Scott RE: Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Mol Cell Biochem 153: 59-67, 1995

    Google Scholar 

  53. Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein tyrosine phosphatase inhibition: Studies on neuronal and glial cell line. J Cell Biochem 59: 389-401, 1995

    Google Scholar 

  54. Fantus IG, Tsiani E: Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic vs. mitogenic effects. Mol Cell Biochem 182: 109-119, 1998

    Google Scholar 

  55. Djordjevic C: Antitumor activity of vanadium compounds. In: H. Sigel and A. Sigel (eds). Biological Systems, Vanadium and Its Role in Life. Marcel Dekker, New York, 1995

    Google Scholar 

  56. Cruz TF, Morgan A, Min W: In vitro and in vivo antineoplastic effects of orthovanadate. Mol Cell Biochem 153: 161-166, 1995

    Google Scholar 

  57. Liasko R, Kabanos TA, Karkabounas S, Malamas M, Tasiopoulas AJ, Stefanou D, Collery P, Evangelou A: Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo (alpha) pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res 18: 3609-3613, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srivastava, A.K. Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206, 177–182 (2000). https://doi.org/10.1023/A:1007075204494

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007075204494

Keywords

Navigation